MLTX - MoonLake Immunotherapeutics
18.14
0.450 2.481%
Share volume: 655,381
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$17.69
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-07-2024 | 11-07-2024 | 02-26-2025 | 05-12-2025 | 11-05-2025 | 02-25-2026 | |
| Assets | ||||||||
| Total Assets | 564.117 M | 544.878 M | 518.213 M | 477.933 M | 511.262 M | 414.335 M | 424.433 M | |
| Current Assets | 553.590 M | 536.882 M | 512.316 M | 474.289 M | 506.264 M | 411.215 M | 421.694 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 88.614 M | 177.008 M | 118.268 M | 267.601 M | 208.564 M | 29.743 M | 59.451 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 458.441 M | 342.791 M | 375.656 M | 180.426 M | 271.566 M | 350.736 M | 334.517 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 509.816 K | 481.705 K | 581.378 K | 722.226 K | 711.000 K | 622.000 K | 577.000 K | |
| Other Assets | 10.017 M | 7.514 M | 5.316 M | 2.922 M | 4.287 M | 2.498 M | 2.162 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 564.117 M | 544.878 M | 518.213 M | 477.933 M | 511.262 M | 414.335 M | 424.433 M | |
| Total liabilities | 11.731 M | 14.846 M | 22.712 M | 24.542 M | 98.681 M | 123.144 M | 119.952 M | |
| Total current liabilities | 8.911 M | 12.282 M | 20.081 M | 22.464 M | 23.981 M | 48.368 M | 45.478 M | |
| Accounts Payable | 3.483 M | 5.143 M | 10.711 M | 8.992 M | 12.006 M | 25.282 M | 29.553 M | |
| Other liabilities | 2.357 M | 2.022 M | 1.936 M | 1.458 M | 1.142 M | 486.000 K | 374.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 73.022 M | 73.741 M | 74.100 M | |
| Other liabilities | 2.357 M | 2.022 M | 1.936 M | 1.458 M | 1.142 M | 486.000 K | 374.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 542.554 M | 520.664 M | 488.195 M | 446.825 M | 407.520 M | 288.906 M | 304.481 M | |
| Common stock | 670.192 M | 672.005 M | 675.350 M | 677.421 M | 680.670 M | 689.114 M | 766.788 M | |
| Retained earnings | -130.331 M | -154.598 M | -189.988 M | -235.593 M | -275.537 M | -400.486 M | -462.911 M |